Yinhua Securities Charity Foundation (YSCF) awards more than $1.1 million in sports medical research grants

YSCF, the charitable foundation of Yinhua Securities, has awarded more than $1.1 million in grants to support sports-related medical research at 15 organizations, the YSCF announced today.

“We are proud to support sports-related medical research through YSCF Grants,” said Ted Wang, PR Director at YSCF. “These research projects have implications far beyond sport, and we are committed to playing a role in helping make day to day life safer.”

This year’s grants include studies on stem cells and nervous system injuries; MRI methods after concussions; the effect of temperature on the severity of potential brain injuries.

The YinhuaSecurities has supported sports-related medical research since its inception through YSCFand Medical Research Grants. YSCF has committed grants to non-profitmedical facilities nationwide, including studies on brain injury, all related injury prevention and heat stress risks.

Project Receiving Grant:

•  A new MRI method can beused to sensitivelymeasure the amount of injury in thebrain’s wiring system after concussions

•  Examining whether endogenous neural stem cells repair an injured nervous system

•  The effects of mild hyperthermia on outcome after mild traumatic brain injury

•  Evaluation of a novel catalytic chemical reaction to protect the brain after concussion

•  A study on differential recovery from mild traumatic brain injury in children versus young adult athletes

•  Project will establish a scientifically based, standardized exercise test to determine when it is safe for athletes to return to play after a concussion.

•  Protein therapeutics for the treatment of traumatic brain injury

•  Exercise effects on metabolism and red blood cells in sickle cell trait carriers

•  Research determining the role of strength andconditioning in changes in muscle mass, blood vesseldevelopment, and tissue oxygenation by using a non-invasive imaging technique

•  The use of platelet-rich plasma and bone marrow-derived stem cell therapy for tendon degeneration

Via EPR Network
More Financial press releases